Matches in Wikidata for { <http://www.wikidata.org/entity/Q98724071> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- Q98724071 description "article scientifique publié en 2020" @default.
- Q98724071 description "artículu científicu espublizáu n'agostu de 2020" @default.
- Q98724071 description "scientific article published on 25 August 2020" @default.
- Q98724071 description "wetenschappelijk artikel" @default.
- Q98724071 description "наукова стаття, опублікована 25 серпня 2020" @default.
- Q98724071 name "Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy" @default.
- Q98724071 name "Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy" @default.
- Q98724071 type Item @default.
- Q98724071 label "Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy" @default.
- Q98724071 label "Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy" @default.
- Q98724071 prefLabel "Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy" @default.
- Q98724071 prefLabel "Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy" @default.
- Q98724071 P1433 Q98724071-A0803402-9E0A-477B-BF48-480003BCAE51 @default.
- Q98724071 P1476 Q98724071-6FB42D72-9A8A-4FB4-88A9-4489BD133AC1 @default.
- Q98724071 P2093 Q98724071-0513EC77-EBB9-445C-A5FD-CE4EB4EBDF00 @default.
- Q98724071 P2093 Q98724071-1240134D-414D-4BC9-9FA8-A85C996B7B1B @default.
- Q98724071 P2093 Q98724071-30D8F5A0-1B91-4393-BBF1-BCBA069776F5 @default.
- Q98724071 P2093 Q98724071-33656D58-794D-4EAE-BEEA-76D62E79B33E @default.
- Q98724071 P2093 Q98724071-3C8F5624-7D79-4544-9A65-3F88DE8FBDDF @default.
- Q98724071 P2093 Q98724071-3F380040-3DCD-4359-904C-F3A10259A596 @default.
- Q98724071 P2093 Q98724071-504DA1FC-5196-4324-8D86-EC65B83236CC @default.
- Q98724071 P2093 Q98724071-5ED48056-A59E-453B-96A0-FD3F30DBC49D @default.
- Q98724071 P2093 Q98724071-7B1882F5-4827-4F45-9497-4B2C7AB0EC5B @default.
- Q98724071 P2093 Q98724071-851C8E92-E544-4CE8-91FE-F80665FA7A40 @default.
- Q98724071 P2093 Q98724071-8666CF62-299D-4BE6-906C-10450EDE9FE1 @default.
- Q98724071 P2093 Q98724071-8AA9A5FB-2136-43AC-A540-44A5C0AD7D50 @default.
- Q98724071 P2093 Q98724071-93DB450C-0F63-4EE3-B8EF-D6F2925E82B5 @default.
- Q98724071 P2093 Q98724071-94C0CB4A-6972-402F-990C-F1E66D6B7015 @default.
- Q98724071 P2093 Q98724071-AB0697D8-FE36-489F-B7C6-979986FFF076 @default.
- Q98724071 P2093 Q98724071-F4C824F2-BA4E-4414-B9BE-79B2216C6167 @default.
- Q98724071 P275 Q98724071-6B188637-C7F6-47AC-B9C7-B2896F3F74B9 @default.
- Q98724071 P304 Q98724071-4F15BDEF-BD7E-4CA3-90DF-18BDEAD425F5 @default.
- Q98724071 P31 Q98724071-C875283B-8AA7-4C83-A1B5-AF8DFEE107A5 @default.
- Q98724071 P356 Q98724071-A3E6A02B-96FA-4D68-9699-3670FDE99727 @default.
- Q98724071 P50 Q98724071-3E978D20-8AF1-4CFA-91CC-2F38BB3EE06C @default.
- Q98724071 P50 Q98724071-7C0EF25C-24FB-4B3E-A5C7-3832B21176F8 @default.
- Q98724071 P50 Q98724071-ED59A6E5-7182-4CD1-AE8D-FCB0EE412C6F @default.
- Q98724071 P577 Q98724071-81E7B908-2383-4556-BE98-C1F9EE38B599 @default.
- Q98724071 P6216 Q98724071-139FDA14-50EB-4B22-81EA-98CC26F1B158 @default.
- Q98724071 P698 Q98724071-5040382C-8009-48E0-9BC9-9466C89D49C1 @default.
- Q98724071 P921 Q98724071-C816454A-3DA8-4887-B92E-E0AFC27EB01D @default.
- Q98724071 P356 10428194.2020.1791846 @default.
- Q98724071 P698 32842815 @default.
- Q98724071 P1433 Q6534493 @default.
- Q98724071 P1476 "Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy" @default.
- Q98724071 P2093 "Anas Younes" @default.
- Q98724071 P2093 "Andrea Gallamini" @default.
- Q98724071 P2093 "Andres Forero-Torres" @default.
- Q98724071 P2093 "Andrew Grigg" @default.
- Q98724071 P2093 "Anna Sureda" @default.
- Q98724071 P2093 "Arpad Illes" @default.
- Q98724071 P2093 "Ashish Gautam" @default.
- Q98724071 P2093 "David Straus" @default.
- Q98724071 P2093 "Graham Collins" @default.
- Q98724071 P2093 "Indra Purevjal" @default.
- Q98724071 P2093 "Joseph Connors" @default.
- Q98724071 P2093 "Keenan Fenton" @default.
- Q98724071 P2093 "Pier Luigi Zinzani" @default.
- Q98724071 P2093 "Sergey Alekseev" @default.
- Q98724071 P2093 "Tae Min Kim" @default.
- Q98724071 P2093 "Valeria Buccheri" @default.
- Q98724071 P275 Q20007257 @default.
- Q98724071 P304 "1-8" @default.
- Q98724071 P31 Q13442814 @default.
- Q98724071 P356 "10.1080/10428194.2020.1791846" @default.
- Q98724071 P50 Q43979926 @default.
- Q98724071 P50 Q59505916 @default.
- Q98724071 P50 Q90023949 @default.
- Q98724071 P577 "2020-08-25T00:00:00Z" @default.
- Q98724071 P6216 Q50423863 @default.
- Q98724071 P698 "32842815" @default.
- Q98724071 P921 Q209369 @default.